Abstract
Many patients with hepatitis C (HCV) suffer from concurrent renal disease requiring dialysis and eventual renal transplant. HCV treatment with direct-acting antivirals (DAA) is safe and effective in the context of renal transplant, but the optimal timing of treatment in proximity to transplant remains a focus of debate. We present the case of a 60-year-old male with HCV genotype 3 infection. He failed two prior interferon-based treatments, underwent previous separate liver and kidney transplants, and is currently under evaluation for a second kidney transplant for end-stage renal disease (ESRD). Using this illustrative case, we discuss topics pertinent to the evaluation and clinical care of HCV-infected renal transplant candidates including evaluation for a simultaneous liver-kidney transplant in the context of HCV infection, optimal timing of HCV treatment with respect to transplantation, and the safety and monitoring requirements during DAA treatment in renal transplant candidates.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call